The use of biologics in lupus has lagged far behind the experience of these agents in rheumatoid arthritis (RA). Lessons learnt in RA (and increasingly in seronegative spondyloarthritis) include the observation that in general the agents now in use are safe, even in the medium to longer term and that they can be used in place of other remedies, if necessary.
Furthermore, they can be used in tandem with other biologics, reaching the stage where ''treat to target'' is now regarded as achievable.
Experience in lupus has been less positive. As Nandkumar and colleagues remind us in this special issue of Lupus, ''while several promising treatments have emerged, only one drug, belimumab, has passed regulatory muster''. Possible reasons for this time lag are many -lupus being less common than RA, the clinical complexity of systemic lupus erythematosus (SLE), the need for additional immunosuppressives in many cases, and of course, the many disappointments in clinical trials along the way.
However, there is cause for optimism. Anti-B cell agents, rituximab and now belimumab, despite early trial setbacks, are both successful additions to our lupus treatment repertoire. They promise to profoundly alter lupus clinical practice.
One example is the ''no-steroid'' regime for lupus nephritis being trialed by Liz Lightstone 1 and her team using an initial two pulses of rituximab (and a pulse of methylprednisolone) followed by maintenance mycophenolate mofetil (MMF) and no oral steroids.
With deepening understanding of the mechanisms leading to lupus activity, a rapidly increasing number of agents are currently in various stages of trial.
Already lessons are being learnt -the heightened risk of infections when biologics are combined with conventional immunosuppressive drugs such as cyclophosphamide and MMF. Plus the (obvious) risk of failure in a drug trial when the background dosage of steroids is high.
In this special issue of Lupus, Professor Dan Wallace, whose clinical experience in this area is second to none, has brought together a number of the leaders in the field of new directed therapies in SLE.
For me, this special issue brings us an important snapshot of the current status of 'biologics' in lupus.
